Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

A European review examined data indicating an increased risk of heart valve regurgitation after use of fluoroquinolones. Information has been added to the product information for these medicines, and they should only be used after careful risk-benefit assessment in those at risk.

Medicines and Healthcare products Regulatory Agency